Study Information
Status: Active, Not Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
Palo Alto/Santa Cruz, Greater Sacramento Valley, East Bay, Modesto, Santa Rosa, San Francisco, San Mateo, Solano/Vallejo
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Principal Investigator
Related Studies
Impact of COVID-19 on Cancer Care Management
Study will enhance understanding of cancer care management due to COVID-19.
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Breast Cancer Chemoprevention in Primary Care at Geisinger
Identify PCPs’ awareness of breast cancer risk assessment and breast cancer chemoprevention knowledge, and identify perceived barriers and clinic solutions.
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
Dana Farber 13-09-259 DCIS Registry
Molecular Characterization of Breast Cancer with Duct Forming Features
Investigator: Kristie A. Bobolis, M.D.